Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy Without An Intracellular Domain (TNFRSF10C) (Extracellular Domain), (AA 149-167) antibody

Details for Product No. ABIN123327
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Epitope
Extracellular Domain, AA 149-167
(11), (9), (7), (4), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human
(92), (7), (6), (5)
Host
Rabbit
(52), (42), (3), (3)
Clonality
Polyclonal
Conjugate
Un-conjugated
(12), (9), (3), (2), (1), (1), (1)
Application
Western Blotting (WB)
(54), (47), (19), (10), (10), (8), (7), (2), (2), (2), (1)
Pubmed 3 references available
Quantity 0.1 mg
Shipping to United States (Change)
Availability Discontinued
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN123327
654.50 $
Plus shipping costs $45.00
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Peptide corresponding to aa 149-167 at the extracellular domain of human DcR1 precursor (4-6)
Purification Protein G chromatography
Alternative Name CD263 / TRAILR3
Background Cells undergo programmed cell death (Apoptosis) in response to various stimuli. Apoptosis is essential for morphogenesis, tissue homeostasis, and host defense. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptors have been recently identified and designated DR4 and DR5 (for death receptor 4). DR4 and DR5 are functional receptors for TRAIL, and DcR1/TRID and DcR2 are decoy receptors1-3. DcR1 is also designated as TRAIL-R3, TRID or LIT2-7. DcR1 has an extracellular TRAIL-binding domain but lacks intracellular death domain and does not induce apoptosis. TRAIL-R3 also has several sites for potential N- (5 sites) and O-linked (approximately 20) glycosylation and GPI addition. Antibodies made against TRAIL-R3/DcR1 detects a protein of approximate molecular mass of 65kDa in the western blot analysis under denaturing and reducing conditions instead of theoretical Mr of 29 kDa6. The slow migration of this protein in SDS-PAGE is probably due to the presence of 5 TAPE (threonine, alanine, proline, and glutamine-rich) repeats. The TAPE repeat- deficient receptor migrates normally in SDS-PAGE6. Unlike TRAIL-R1 (DR4) and TRAIL-R2 (DR5), DcR1/TRAIL-R3 transcript is restricted to skeletal muscle, peripheral blood lymphocytes, and the spleen. Alternate Names: TRAIL-R3, TRID, LIT, CD263.
UniProt O14798
Research Area Signaling, Apoptosis/Necrosis
Application Notes Western blot: 1 ug/ml. Recommended positive control: 293 or HeLa. A 65 kDa band is observed. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer PBS containing 0.02 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Store the antibody at 2 - 8 °C up to six months or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing. Shelf Life: one year from despatch.
Expiry Date 12 months
Supplier Images
anti-Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy Without An Intracellular Domain (TNFRSF10C) (Extracellular Domain), (AA 149-167) antibody Western blot analysis of 20 ug of whole cell lysate from HeLa (Lane 1) and 293 (Lane 2) cells with anti-DcR2 at 1 ug/ml dilution.
General Pan, ORourke, Chinnaiyan et al.: "The receptor for the cytotoxic ligand TRAIL." in: Science (New York, N.Y.), Vol. 276, Issue 5309, pp. 111-3, 1997 (PubMed).

Pan, Ni, Wei et al.: "An antagonist decoy receptor and a death domain-containing receptor for TRAIL." in: Science (New York, N.Y.), Vol. 277, Issue 5327, pp. 815-8, 1997 (PubMed).

Degli-Esposti, Smolak, Walczak et al.: "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family." in: The Journal of experimental medicine, Vol. 186, Issue 7, pp. 1165-70, 1997 (PubMed).

Validation Images
Did you look for something else?
back to top